Psoriasis and Psoriatic Disorders News

Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program - Business Wire (press release)



Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program 
Business Wire (press release)
PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLAŽ exerts its therapeutic action in patients with psoriasis or ...

and more » 


Analyzing Versartis (VSAR) & Prothena Corporation PLC (NASDAQ:PRTA) - Dispatch Tribunal



Analyzing Versartis (VSAR) & Prothena Corporation PLC (NASDAQ:PRTA) 
Dispatch Tribunal
... Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind ...

and more » 


Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis - Labiotech.eu (blog)



Labiotech.eu (blog)
 
Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis 
Labiotech.eu (blog)
Psoriasis is a common autoimmune disorder that affects the skin, often causing patches of dry, itchy, and painful lesions. In severe cases, people can develop psoriatic arthritis, which can lead to painful inflammation in the joints. According to the ...

 


J&J psoriasis drug gets expanded US approval for teens - Reuters



Reuters
 
J&J psoriasis drug gets expanded US approval for teens 
Reuters
It is also approved to treat adults with the related condition psoriatic arthritis, and for moderate to severe Crohn's disease. About one-third of people who develop plaque psoriasis do so before 20 years of age, J&J said. ?Psoriasis is a highly ...

 


Stelara Approved for Use in Adolescents With Plaque Psoriasis - Managed Care magazine



European Pharmaceutical Review
 
Stelara Approved for Use in Adolescents With Plaque Psoriasis 
Managed Care magazine
It is also indicated for the treatment of adult patients 18 years and older with active psoriatic arthritis, alone or with the medicine methotrexate, and for the treatment of adult patients 18 years or older with moderately to severely active Crohn's ...
Janssen announces FDA approval of Stelara for plaque psoriasis European Pharmaceutical Review
Psoriasis Drug Approved for Teen Use Newsmax (blog)
J & J psoriasis drug gets USFDA nod for expanded use among ... International Business Times, Singapore Edition

all 14 news articles » 


J&J psoriasis drug gets expanded U.S. approval for teens - Business ... - Business Insider



J&J psoriasis drug gets expanded U.S. approval for teens - Business ... 
Business Insider
Oct 13 (Reuters) - Johnson & Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent ...

and more » 


Janssen Announces US FDA Approval Of STELARAŽ (ustekinumab) For The Treatment Of Adolescents With Moderate ... - PR Newswire (press release)



Janssen Announces US FDA Approval Of STELARAŽ (ustekinumab) For The Treatment Of Adolescents With Moderate ... 
PR Newswire (press release)
"Psoriasis is a highly visible disease, and it is essential that these younger patients and their caregivers have options that can effectively reduce the difficult-to-conceal and often misunderstood plaques," said Michael Siegel, Ph.D., Senior Vice ...

and more » 


PWD struggles in a developing country | SunStar - Sun.Star



PWD struggles in a developing country | SunStar 
Sun.Star
ONE of my kids was recently diagnosed with psoriasis, a chronic autoimmune skin disorder which causes rapid multiplication of skin cells. This disease results in ...

and more » 


Financial Contrast: Epirus Biopharmaceuticals (EPRS) & Its Rivals - Week Herald



Financial Contrast: Epirus Biopharmaceuticals (EPRS) & Its Rivals 
Week Herald
... is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare ...

 


Head-To-Head Analysis: Prothena Corporation PLC (PRTA) and ... - Week Herald



Head-To-Head Analysis: Prothena Corporation PLC (PRTA) and ... 
Week Herald
Versartis (NASDAQ: VSAR) and Prothena Corporation PLC (NASDAQ:PRTA) are both medical companies, but which is the superior stock? We will compare the ...

and more »